Roivant Sciences Ltd. [NASDAQ: ROIV] plunged by -$0.95 during the normal trading session on Thursday and reaching a high of $8.29 during the day while it closed the day at $7.59. The company report on February 2, 2023 that Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. are acting as bookrunning managers for the offering.
Roivant Sciences Ltd. stock has also loss -9.32% of its value over the past 7 days. However, ROIV stock has inclined by 43.21% in the 3 months of the year. Over the past six months meanwhile, it has gained 100.26% and lost -5.01% year-on date.
The market cap for ROIV stock reached $5.39 billion, with 699.89 million shares outstanding and 440.82 million shares in the current float. Compared to the average trading volume of 2.21M shares, ROIV reached a trading volume of 4581572 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Roivant Sciences Ltd. [ROIV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ROIV shares is $13.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ROIV stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Roivant Sciences Ltd. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 27, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Outperform. The new note on the price target was released on May 23, 2022, representing the official price target for Roivant Sciences Ltd. stock. Previously, the target price had yet another raise to $15, while Cantor Fitzgerald analysts kept a Overweight rating on ROIV stock.
The Average True Range (ATR) for Roivant Sciences Ltd. is set at 0.51, with the Price to Sales ratio for ROIV stock in the period of the last 12 months amounting to 106.95. The Price to Book ratio for the last quarter was 4.57, with the Price to Cash per share for the same quarter was set at 2.25.
ROIV stock trade performance evaluation
Roivant Sciences Ltd. [ROIV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.32. With this latest performance, ROIV shares gained by 6.15% in over the last four-week period, additionally plugging by 100.26% over the last 6 months – not to mention a rise of 6.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ROIV stock in for the last two-week period is set at 41.33, with the RSI for the last a single of trading hit 32.82, and the three-weeks RSI is set at 46.91 for Roivant Sciences Ltd. [ROIV]. The present Moving Average for the last 50 days of trading for this stock 7.50, while it was recorded at 8.25 for the last single week of trading, and 4.95 for the last 200 days.
Roivant Sciences Ltd. [ROIV]: An insightful look at the core fundamentals
Reflecting on the efficiency of the workforce at the company, Roivant Sciences Ltd. [ROIV] managed to generate an average of -$193,201 per employee.Roivant Sciences Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.40 and a Current Ratio set at 7.40.
Roivant Sciences Ltd. [ROIV]: Insider Ownership positions
There are presently around $2,808 million, or 51.20% of ROIV stock, in the hands of institutional investors. The top three institutional holders of ROIV stocks are: QVT FINANCIAL LP with ownership of 129,393,817, which is approximately 0% of the company’s market cap and around 14.50% of the total institutional ownership; SB INVESTMENT ADVISERS (UK) LTD, holding 99,375,586 shares of the stock with an approximate value of $754.26 million in ROIV stocks shares; and VIKING GLOBAL INVESTORS LP, currently with $669.73 million in ROIV stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Roivant Sciences Ltd. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 47 institutional holders increased their position in Roivant Sciences Ltd. [NASDAQ:ROIV] by around 13,882,648 shares. Additionally, 25 investors decreased positions by around 4,678,242 shares, while 19 investors held positions by with 351,392,525 shares. The mentioned changes placed institutional holdings at 369,953,415 shares, according to the latest SEC report filing. ROIV stock had 18 new institutional investments in for a total of 3,314,989 shares, while 8 institutional investors sold positions of 2,771,810 shares during the same period.